These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33410265)

  • 1. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Yokozeki H; Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S
    J Dermatol; 2021 Mar; 48(3):279-288. PubMed ID: 33410265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S; Yokozeki H
    J Dermatol; 2021 Aug; 48(8):1149-1161. PubMed ID: 34041788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis.
    Fujimoto T; Okatsu H; Miyama H
    J Dermatol; 2022 Jun; 49(6):594-599. PubMed ID: 35394087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
    Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
    J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 5% sofpironium bromide gel in Duchenne muscular dystrophy with palmoplantar hyperhidrosis: A retrospective case study.
    Funato M; Iwata R; Iimoto M
    J Dermatol; 2024 Jan; 51(1):135-139. PubMed ID: 37795807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
    Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
    J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofpironium Bromide: First Approval.
    Paik J
    Drugs; 2020 Dec; 80(18):1981-1986. PubMed ID: 33236266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
    Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
    Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
    Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis.
    Gregoriou S; Tsiogka A; Kontochristopoulos G; Offidani A; Campanati A
    Expert Opin Investig Drugs; 2022 Jan; 31(1):15-21. PubMed ID: 34890517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
    J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
    Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
    J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
    Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
    Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance.
    Hobart J; Burke L; Kirsch B; Chadha D
    J Drugs Dermatol; 2021 Apr; 20(4):410-418. PubMed ID: 33852243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
    Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
    Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
    Nasir A; Bissonnette R; Maari C; DuBois J; Pene Dumitrescu T; Haddad J; Yamaguchi Y; Dalessandro M
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):145-151. PubMed ID: 29055158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
    Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F
    Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study.
    Amano Y; Mazda J; Amano K; Ohi K; Shioiri T
    BJPsych Open; 2023 Jan; 9(1):e14. PubMed ID: 36636808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.